NASDAQ · GALT
Galectin Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GALT: Nov 13, 2026
Galectin Therapeutics Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Dec 2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Aug 19, 3:15 AM EDTGalectin Loss Widens In Q2; Plans Phase 3 MASH Trial For Q3 2026(RTTNews) – Galectin Therapeutics Inc. (GALT), a clinical-stage biotech company, a week-ago reported second quarter results showing a wider loss due to higher expenses, mainly associated with a change in fair value of derivatives and interest expense.
- RTTNews · Jul 13, 10:30 PM EDTTop Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus(RTTNews) – Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full
- RTTNews · Jun 24, 11:47 PM EDTTop Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High(RTTNews) – Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose ProSense technology was validated in an article published in the International
- Zacks · Jun 24, 10:05 AM EDTGALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASHGalectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
- RTTNews · Jun 23, 11:13 PM EDTTop Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment(RTTNews) – Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and Galectin Therapeutics, which has reached
- RTTNews · Jun 23, 11:05 AM EDTGalectin Aligns With FDA Feedback To Advance Belapectin In MASH Cirrhosis And Portal Hypertension(RTTNews) – Galectin Therapeutics Inc. (GALT), a clinical-stage biotechnology company, announced that it reached alignment with the U.S. Food and Drug Administration during a recent in-person Type C meeting on the primary endpoint and regulatory path forward for Belapectin in Met
- RTTNews · May 11, 11:50 AM EDTGalectin Rises After Publishing Positive Phase 2b Data For Belapectin In Treating MASH Cirrhosis(RTTNews) – Galectin Therapeutics Inc. (GALT), a clinical-stage biotechnology company, on Monday published promising results from the Phase 2b NAVIGATE trial for belapectin in treating MASH cirrhosis and portal hypertension in AASLD flagship journal Hepatology.
- Zacks · Apr 3, 12:00 PM EDTGalectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Dec 26, 8:50 AM ESTWeekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets(RTTNews) – In a holiday-shortened week, the biotech sector saw a wave of FDA approvals, strategic acquisitions, and key clinical trial readouts – alongside several setbacks that shaped the sector's outlook.
- RTTNews · Dec 22, 2:52 AM ESTGalectin Advances Belapectin Program With FDA Feedback And Secures $10 Million Credit Line(RTTNews) – Galectin Therapeutics Inc. (GALT) Friday announced that the U.S. FDA has provided written feedback on its development program for Belapectin, the company's investigational galectin-3 inhibitor for patients with MASH cirrhosis and portal hypertension.
- Fintel · Dec 20, 8:27 PM ESTGalectin Therapeutics (GALT) Price Target Increased by 83.33% to 11.22The average one-year price target for Galectin Therapeutics (NasdaqCM:GALT) has been revised to $11.22 / share. This is an increase of 83.33% from the prior estimate of $6.12 dated December 3, 2025. The price target is an average of many targets provided by an
- RTTNews · Dec 18, 11:27 PM ESTAfter-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers(RTTNews) – Several small-cap biotech and healthcare names posted notable gains in Thursday's after-hours trading session, with investors reacting to recent corporate updates and clinical milestones.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Galectin Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.